Oesophageal Cancer: Global Clinical Trial Landscape (2024)

Explore Novotech CRO's disease report on oesophageal cancer to discover the latest in treatments, clinical trials, and future innovations.

Oesophageal cancer is the 11th most common cancer and 7th leading cause of cancer deaths, starting in the esophagus. The main types—oesophageal adenocarcinoma and oesophageal squamous cell carcinoma—affect different parts of the esophagus and are driven by unique genetic changes. Symptoms often go unnoticed until the cancer progresses. With early detection, the five-year survival rate can improve significantly, though it currently ranges from 5% to 50%. The number of new cases is projected to surpass 923,000 annually by 2050.

Current treatment guidelines from NCCN, ESMO, and the Japan Oesophageal Society recommend various chemotherapy regimens and immune checkpoint inhibitors. In 2022, there were around 511,000 new cases and 445,400 deaths worldwide, with the highest rates in Asia.

Since 2019, over 1,500 trials have been initiated, with significant activity in Asia-Pacific, North America, and Europe. Major companies are advancing therapies, including antibodies and small molecules. Novotech, a leading global CRO, supports extensive oncology projects and has been recognized for its contributions.

Download our report for comprehensive insights into the oesophageal cancer clinical trial landscape.